Carbonic anhydrase inhibitors (CAIs) decrease cardiac amyloid β pathology, mitigating neuro‐signaling maladaptive remodeling and improving cardiac function in Tg2676‐ AD mouse model

These findings suggest a new beneficial role of CAIs in preventing the Aβ-induced cardiovascular remodeling and neuro-signaling deregulation for the first time in the Tg2576 model of AD. Taken together with the positive effects of CAIs on cerebrovascular function and cognition, this study paves the way for future clinical trials aimed at repurposing FDA-approved CAIs to prevent and correct both central and peripheral pathologies induced by AD and amyloidosis.